SOURCE: EyeGate Pharma

September 05, 2007 08:01 ET

EyeGate Pharma to Showcase EyeGate II Delivery System to Inflammatory Ocular Disease Specialists at IOIS Congress

WALTHAM, MA--(Marketwire - September 5, 2007) - EyeGate Pharma, a privately held, specialty pharmaceutical company pioneering the use of iontophoresis technology to safely and non-invasively deliver therapeutics for ocular indications, today announced that the company is a corporate sponsor of the 9th Congress of the International Ocular Inflammation Society (IOIS), which will be held in Paris, France, at the Meridien Etoile Hotel from September 17 - 20, 2007.

In addition to sponsoring IOIS, Stephen From, President and Chief Executive Officer of EyeGate Pharma, will be hosting a reception where he will give a detailed presentation of the EyeGate® II Delivery System to a group of international uveitis experts. The presentation will feature progress made with non-invasive, ocular iontophoresis drug delivery, as well as clinical and pre-clinical data generated at EyeGate in uveitis and other inflammatory ocular diseases. Mr. From will be available during the congress for one-on-one meetings.

IOIS is a bi-annual medical meeting that brings international inflammatory ocular diseases specialists together with the world's foremost societies dedicated to ocular inflammation. For more information, visit www.iois-paris-2007.com/

About EyeGate Pharma

EyeGate Pharma was founded in 1998 with technology licensed from Bascom Palmer Eye Institute at the University of Miami. EyeGate's transscleral (across the sclera, or white protective outer membrane of the eye) iontophoresis delivery platform, the EyeGate® II Delivery System, was designed by ophthalmologists for ophthalmologists. This non-invasive system can be applied to safely deliver a wide range of therapeutics to both the anterior and posterior chambers of the eye. An 89-patient pilot study, using the Company's first-generation delivery device, demonstrated exceptional patient tolerance with a significant decrease in inflammatory markers and a concurrent increase in visual acuity. A typical application takes less than five minutes and has been shown to be extremely well tolerated in patients suffering from severe uveitis and other inflammatory ocular diseases. Clinical studies utilizing the EyeGate® II Delivery System are scheduled to begin in 2008. For more information please visit www.eyegatepharma.com/

Contact Information